TABLE 1.
European Society of Cardiology/European Respiratory Society risk assessment parameters in the PATENT-2 study population at baseline and follow-up of PATENT-1
| Riociguat# | Placebo | |||
| Baseline | Follow-up | Baseline | Follow-up | |
| Subjects | 231 | 109 | ||
| 6MWD risk group | ||||
| Missing | 0 | 3 (1) | 0 | 1 (1) |
| Low: >440 m | 26 (11) | 75 (32) | 15 (14) | 32 (29) |
| Intermediate: 165–440 m | 202 (87) | 152 (66) | 94 (86) | 76 (70) |
| High: <165 m | 3 (1) | 1 (<1) | 0 | 0 |
| WHO FC risk group | ||||
| Missing | 0 | 3 (1) | 1 (1) | 1 (1) |
| Low: I/II | 103 (45) | 142 (61) | 57 (52) | 62 (57) |
| Intermediate: III | 128 (55) | 85 (37) | 49 (45) | 44 (40) |
| High: IV | 0 | 1 (<1) | 2 (2) | 2 (2) |
| NT-proBNP risk group | ||||
| Missing | 21 (9) | 4 (2) | 12 (11) | 3 (3) |
| Low: <300 pg·mL−1 | 94 (41) | 122 (53) | 32 (29) | 36 (33) |
| Intermediate: 300–1400 pg·mL−1 | 65 (28) | 82 (35) | 39 (36) | 36 (33) |
| High: >1400 pg·mL−1 | 51 (22) | 23 (10) | 26 (24) | 34 (31) |
| RAP risk group | ||||
| Missing | 1 (<1) | 2 (1) | 5 (5) | 6 (6) |
| Low: <8 mmHg | 131 (57) | 138 (60) | 62 (57) | 51 (47) |
| Intermediate: 8–14 mmHg | 72 (31) | 74 (32) | 37 (34) | 39 (36) |
| High: >14 mmHg | 27 (12) | 17 (7) | 5 (5) | 13 (12) |
| Cardiac index risk group | ||||
| Missing | 3 (1) | 4 (2) | 5 (5) | 6 (6) |
| Low: ≥2.5 L·min−1·m−2 | 102 (44) | 172 (74) | 52 (48) | 46 (42) |
| Intermediate: 2.0–2.5 L·min−1·m−2 | 83 (36) | 40 (17) | 21 (19) | 30 (28) |
| High: <2.0 L·min−1·m−2 | 43 (19) | 15 (6) | 31 (28) | 27 (25) |
| SvO2 risk group | ||||
| Missing | 26 (11) | 11 (5) | 12 (11) | 11 (10) |
| Low: >65% | 106 (46) | 154 (67) | 56 (51) | 47 (43) |
| Intermediate: 60–65% | 46 (20) | 36 (16) | 26 (24) | 25 (23) |
| High: <60% | 53 (23) | 30 (13) | 15 (14) | 26 (24) |
Data are presented as n or n (%). 6MWD: 6-min walk distance; WHO: World Health Organization; FC: functional class; NT-proBNP: N-terminal pro-brain natriuretic peptide; RAP: right atrial pressure; SvO2: mixed venous oxygen saturation. #: riociguat 2.5 mg three times daily maximum.